Appili Therapeutics Announces Additional Funding of CAD$2.5 million under Non-Convertible Secured Loan with Long Zone Holdings
Summary
By systematically identifying urgent infections with unmet needs, Appilis goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. Long Zone holds a number of significant positions in pharmaceutical and health related companies including specialty pharma Knight Therapeutics Inc. (www.knighttx.com) (TSE: GUD) IBS gut friendly privately held Fody Foods Company Inc. (www.fodyfoods.com), and secured debt in a privately-held U.S. generic manufacturer and distributor.This news release contains forward-looking statements, including with respect to the timing of funding and the proposed use proceeds. Wherever possible, words such as may , would, could , should, will, anticipate, believe, plan, expect, intend, estimate, potential for and similar expressions have been used to identify these forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.
Funding
Review available funding amount, funding date, investors, and linked company information related to Appili Therapeutics Announces Additional Funding of CAD$2.5 million under Non-Convertible Secured Loan with Long Zone Holdings in the interactive ISVWorld profile.